FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097722415> ?p ?o ?g. }

• W3097722415 endingPage "22" @default.
• W3097722415 startingPage "21" @default.
• W3097722415 abstract "Background: Several recent studies support the notion of excessive complement activation in patients with severe coronavirus disease-19 (COVID-19), with beneficial results of complement inhibition in case series. In this context, severe COVID-19 shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). TMA is commonly characterized by genetic susceptibility, and presents with thrombocytopenia, anemia, increased lactate dehydrogenase (LDH), and organ damage (renal, neurological, cardiac). Aims: We hypothesized that genetic susceptibility would be also evident in patients with severe COVID-19 and would be associated with disease severity. Methods: We prospectively studied consecutive adult patients hospitalized with COVID-19 in our referral centers (April-May 2020). Diagnosis was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). COVID-19 severity was assessed based on World Health Organization's (WHO) criteria into moderate/severe, and critical disease. Additional data on patients' history and course were recorded by treating physicians that followed patients up to discharge or death. Patients' DNA was obtained from peripheral blood samples. Probes were designed using the Design studio (Illumina). Amplicons cover exonic regions of TMA-associated genes (Complement factor H/CFH, CFH-related, CFI, CFB, CFD, C3, CD55, C5, MCP, thombomodulin/THBD, ADAMTS13) spanning 15 bases into the intronic regions. We used 10ng of initial DNA material. Libraries were quantified using Qubit and sequenced on a MiniSeq System in a 2x150 bp run. Analysis was performed using the TruSeq Amplicon application (BaseSpace). Alignment was based on the banded Smith-Waterman algorithm in the targeted regions (specified in a manifest file). We performed variant calling with the Illumina-developed Somatic Variant Caller in germline mode and variant allele frequency higher than 20%. Both Ensembl and Refseq were used for annotation of the output files. Variants clinical significance was based on ClinVar and the current version of the Complement Database, as we have previously described. Results: We studied 60 patients, 40 with moderate/severe disease hospitalized in COVID-19 general ward (GW) and 20 with critical disease hospitalized in intensive care units (ICU). Among them, 11 patients succumbed due to COVID-19 disease. Patients laboratory characteristics are shown in Figure. In genetic analysis, patients presented heterogeneous variant profiles including pathogenic, benign, likely benign, and variants of unknown significance (median number of variants: 62, range: 51-89). Search in the Complement Database revealed seven patients, each carrying one pathogenic or likely pathogenic variant in C3, CD46, DGKE, and CFH. Based on ClinVar, we found a pathogenic variant of ADAMTS13 (rs2301612, missense) in 28 patients. We also detected two missense risk factor variants, previously detected in complement-related diseases: rs2230199 in C3 (13 patients); and rs800292 in CFH (26 patients). Among them, 22 patients had a combination of these characterized variants. This combination was significantly associated with critical disease that required intensive care (p=0.037), as well as low lymphocyte counts (p=0.021) and high neutrophil-to-lymphocyte ratio (p=0.050). In the multivariate model, critical disease was an independent predictor of double heterozygocity in these variants. Furthermore, one patient had a rare germline missense variant in CFI (rs112534524), previously detected in complement-related diseases. This patient suffered from critical disease but survived after long-term ICU hospitalization. Interestingly, five patients showed a likely protective missense variant in CFB (rs641153). Conclusion: We have detected for the first time rare and pathogenic TMA-associated variants in patients with severe COVID-19. Our findings of variants in complement-regulatory genes and ADAMTS13 suggest genetic susceptibility and define proof-of-concept for proper selection of patients that would benefit from complement inhibition. Table Disclosures Gavriilaki: Omeros Pharmaceuticals: Consultancy." @default.
• W3097722415 created "2020-11-09" @default.
• W3097722415 creator A5001778425 @default.
• W3097722415 creator A5014867375 @default.
• W3097722415 creator A5018221472 @default.
• W3097722415 creator A5023443876 @default.
• W3097722415 creator A5024888236 @default.
• W3097722415 creator A5025805658 @default.
• W3097722415 creator A5035421071 @default.
• W3097722415 creator A5040235060 @default.
• W3097722415 creator A5040659385 @default.
• W3097722415 creator A5042276325 @default.
• W3097722415 creator A5043443606 @default.
• W3097722415 creator A5045301155 @default.
• W3097722415 creator A5047001713 @default.
• W3097722415 creator A5050822957 @default.
• W3097722415 creator A5051463822 @default.
• W3097722415 creator A5057695305 @default.
• W3097722415 creator A5061193434 @default.
• W3097722415 creator A5063004210 @default.
• W3097722415 creator A5080651334 @default.
• W3097722415 creator A5081134310 @default.
• W3097722415 creator A5084015420 @default.
• W3097722415 creator A5086754307 @default.
• W3097722415 date "2020-11-05" @default.
• W3097722415 modified "2023-10-17" @default.
• W3097722415 title "Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients" @default.
• W3097722415 doi "https://doi.org/10.1182/blood-2020-139304" @default.
• W3097722415 hasPublicationYear "2020" @default.
• W3097722415 type Work @default.
• W3097722415 sameAs 3097722415 @default.
• W3097722415 citedByCount "0" @default.
• W3097722415 crossrefType "journal-article" @default.
• W3097722415 hasAuthorship W3097722415A5001778425 @default.
• W3097722415 hasAuthorship W3097722415A5014867375 @default.
• W3097722415 hasAuthorship W3097722415A5018221472 @default.
• W3097722415 hasAuthorship W3097722415A5023443876 @default.
• W3097722415 hasAuthorship W3097722415A5024888236 @default.
• W3097722415 hasAuthorship W3097722415A5025805658 @default.
• W3097722415 hasAuthorship W3097722415A5035421071 @default.
• W3097722415 hasAuthorship W3097722415A5040235060 @default.
• W3097722415 hasAuthorship W3097722415A5040659385 @default.
• W3097722415 hasAuthorship W3097722415A5042276325 @default.
• W3097722415 hasAuthorship W3097722415A5043443606 @default.
• W3097722415 hasAuthorship W3097722415A5045301155 @default.
• W3097722415 hasAuthorship W3097722415A5047001713 @default.
• W3097722415 hasAuthorship W3097722415A5050822957 @default.
• W3097722415 hasAuthorship W3097722415A5051463822 @default.
• W3097722415 hasAuthorship W3097722415A5057695305 @default.
• W3097722415 hasAuthorship W3097722415A5061193434 @default.
• W3097722415 hasAuthorship W3097722415A5063004210 @default.
• W3097722415 hasAuthorship W3097722415A5080651334 @default.
• W3097722415 hasAuthorship W3097722415A5081134310 @default.
• W3097722415 hasAuthorship W3097722415A5084015420 @default.
• W3097722415 hasAuthorship W3097722415A5086754307 @default.
• W3097722415 hasBestOaLocation W30977224151 @default.
• W3097722415 hasConcept C104317684 @default.
• W3097722415 hasConcept C111684460 @default.
• W3097722415 hasConcept C126322002 @default.
• W3097722415 hasConcept C14356644 @default.
• W3097722415 hasConcept C151730666 @default.
• W3097722415 hasConcept C203014093 @default.
• W3097722415 hasConcept C2777637130 @default.
• W3097722415 hasConcept C2777878052 @default.
• W3097722415 hasConcept C2779134260 @default.
• W3097722415 hasConcept C2779343474 @default.
• W3097722415 hasConcept C49105822 @default.
• W3097722415 hasConcept C54355233 @default.
• W3097722415 hasConcept C71924100 @default.
• W3097722415 hasConcept C8185291 @default.
• W3097722415 hasConcept C86803240 @default.
• W3097722415 hasConcept C8891405 @default.
• W3097722415 hasConcept C90924648 @default.
• W3097722415 hasConceptScore W3097722415C104317684 @default.
• W3097722415 hasConceptScore W3097722415C111684460 @default.
• W3097722415 hasConceptScore W3097722415C126322002 @default.
• W3097722415 hasConceptScore W3097722415C14356644 @default.
• W3097722415 hasConceptScore W3097722415C151730666 @default.
• W3097722415 hasConceptScore W3097722415C203014093 @default.
• W3097722415 hasConceptScore W3097722415C2777637130 @default.
• W3097722415 hasConceptScore W3097722415C2777878052 @default.
• W3097722415 hasConceptScore W3097722415C2779134260 @default.
• W3097722415 hasConceptScore W3097722415C2779343474 @default.
• W3097722415 hasConceptScore W3097722415C49105822 @default.
• W3097722415 hasConceptScore W3097722415C54355233 @default.
• W3097722415 hasConceptScore W3097722415C71924100 @default.
• W3097722415 hasConceptScore W3097722415C8185291 @default.
• W3097722415 hasConceptScore W3097722415C86803240 @default.
• W3097722415 hasConceptScore W3097722415C8891405 @default.
• W3097722415 hasConceptScore W3097722415C90924648 @default.
• W3097722415 hasIssue "Supplement 1" @default.
• W3097722415 hasLocation W30977224151 @default.
• W3097722415 hasLocation W30977224152 @default.
• W3097722415 hasOpenAccess W3097722415 @default.
• W3097722415 hasPrimaryLocation W30977224151 @default.
• W3097722415 hasRelatedWork W2035128042 @default.
• W3097722415 hasRelatedWork W2110518735 @default.
• W3097722415 hasRelatedWork W2167620679 @default.

• next